IGF2 and breast carcinoma: A major mechanism of resistance to anti-IGF-1R drugs involves the IR, which is commonly overexpressed in breast cancer and predominantly expressed as the so called ‘fetal isoform’ (IR-A), which is a bona fide receptor for IGF-2 and proinsulin [11, 12].